Loss of the DNA mismatch repair (MMR) protein MSH3 leads to the development of a variety of tumors in mice without significantly affecting survival rates, suggesting a modulating role for the MutSb (MSH2-MSH3) complex in late-onset tumorigenesis. To better study the role of MSH3 in tumor progression, we crossed Msh3 À / À mice onto a tumor predisposing p53-deficient background. Survival of Msh3/p53 mice was not reduced compared with p53 single mutant mice; however, the tumor spectrum changed significantly from lymphoma to sarcoma, indicating MSH3 as a potent modulator of p53-driven tumorigenesis. Interestingly,
INTRODUCTION
DNA mismatch repair (MMR) complexes function primarily in the detection and repair of mismatched bases that result from erroneous replication. Two heterodimeric MutS homolog (MSH) complexes, consisting of either MSH2-MSH6 (MutSa) or MSH2-MSH3 (MutSb), are responsible for the recognition of these mismatched bases. MSH2-MSH6 binds to single base-base mismatches and small insertions/deletions, whereas MSH2-MSH3 has a higher affinity for X2 base insertions/deletions. 1, 2 Germline mutations in MSH2 and MSH6 but not MSH3 are responsible for hereditary non-polyposis colorectal cancer/Lynch syndrome (HNPCC/LS); however, an (A)8 tract in the coding region of MSH3 was found to be frequently affected by frameshift mutations in MMR-deficient colorectal tumors, resulting in the loss of MSH3 protein expression. 3 In addition to its role in MMR, yeast studies revealed that during non-conservative homologous recombination, the MSH2-MSH3 complex is required to remove nonhomologous DNA ends during both the initiation of gene conversion and the resolution of single-strand annealing (SSA) intermediates that are initiated by a double-strand break (DSB). 4, 5 SSA is a subset of the homologous recombination pathway for repairing spontaneous and induced DSBs that arise between repeated sequences occurring in cis. MSH2 and MSH3 recognize and stabilize the nonhomologous 3 0 tails at the junction of doublestranded and single-stranded DNA to aid in either the recruitment or cleavage activity of Rad1-Rad10. 6 Although the mechanistic contribution of MSH3 in MMR and double-strand break repair (DSBR) was thought to be overlapping, recent studies have shown that these two MSH3 activities are molecularly distinct. 7 MSH2-MSH3 is also involved in triplet repeat (CAG Á CTG) expansion diseases such as Huntington and myotonic dystrophy, and it has been shown in several mouse models that MSH2 and MSH3 are absolutely required to generate these expansions. [8] [9] [10] [11] [12] Previous observations showed that inactivation of Msh3 in mice leads to a moderate defect in the repair of insertion/deletion but not base-base mismatches, 13 which might explain the absence of MSH3 mutations in HNPCC/LS families. Among other tumors,
Msh3
À / À mice developed gastrointestinal tumors late in life, which corresponds with loss of MSH3 expression in late-onset sporadic colorectal cancer in humans. 14 In human cancers, loss of MSH3 is associated with an (microsatellite instability) MSI-low (MSI-L) phenotype at dinucleotide repeats and elevated microsatellite alterations at selected tetranucleotide repeats (EMAST). 15, 16 Loss or silencing of MSH3 also frequently occurs in a variety of other cancers, including non-small cell lung, 17 ovarian, bladder, 18 and breast 19 cancer. MSH3 polymorphisms were found to be associated with sporadic colorectal, 14, 20, 21 prostate, 22 and lung 23 cancer. These findings correlate with a recent report that unlike MutSa, the MutSb complex is abundant in the majority of mouse tissues. 24 Taken together, these studies indicate that MSH2-MSH3 might be important for tumor suppression in multiple tissues and especially in cases of late-onset tumorigenesis.
Previous studies in mice showed that loss of Msh2 is sufficient to initiate and significantly accelerate tumorigenesis, especially in p53-deficient mice, and that tumorigenesis is associated with an MSIhigh (MSI-H) phenotype. 25 The MSH2-MSH6 complex is essential for the repair of base/base mismatches, and loss of either MSH2 or MSH6 therefore results in generation of a severe mutator phenotype and early-onset cancers. In contrast, the absence of MSH3 mutations in early-onset HNPCC/LS tumors and the late-onset tumor phenotype in Msh3 À / À mice indicate that MSH3 is likely not involved in tumor initiation. To determine a possible role for MSH2-MSH3 in tumor progression, we crossed Msh3-null mice onto the tumor predisposing p53-null background to create cohorts of both Msh3 À / À p53 À / À and Msh3 À / À p53 þ / À mice, compared their cancer predisposition phenotype with MMR-deficient Msh2/p53-mutant mice and analyzed the underlying molecular mechanisms. Although the effects of both Msh2-and Msh3-deficiency manifest from the earliest stages of life, tumor onset in Msh3
mice occurred later in life in contrast to the early-onset tumorigenesis in Msh2 À / À p53 À / À mice. We found that because of its role in DSBR in addition to MMR, loss of Msh3 alters the tumor spectrum in p53-mutant mice by modulating the characteristics of the chromosomal instability (CIN) phenotype, resulting in elevated sarcomagenesis. We conclude that germline mutations in Msh3 can cause late-onset tumorigenesis with various genomic signatures and modulate the tumor spectrum on cancer predisposing backgrounds.
RESULTS
Altered cancer phenotype and elevated sarcomagenesis in Msh3/ p53-mutant mice To accelerate tumorigenesis in Msh3-null mice and study tumor progression, we intercrossed Msh3 þ / À -and p53 þ / À -knockout mice and generated two cohorts of mutant mice carrying homozygous mutations in Msh3 and either homozygous (Msh3 Figure 1a ) when compared with Msh3
À / À alone (22 months), 13 but not when compared with p53
À / À single-mutant mice (P ¼ 0.31, Figure 1a ). Msh3
þ / À and p53 þ / À mice also showed similar survival rates (P ¼ 0.11), suggesting that loss of Msh3 does not contribute to the initiation or acceleration of tumorigenesis. In contrast, Msh2 
þ / À tumor samples using PCR (see also À / À p53-driven tumorigenesis.
LOH but not somatic mutation leads to loss of the wild-type p53 allele in Msh3
During tumorigenesis, MMR deficiency leads to the accumulation of somatic mutations in tumor suppressor genes and oncogenes.
On the other hand, tumors with CIN usually display loss of heterozygosity (LOH) of tumor suppressor genes, which is often associated with defective DSBR pathways. 31 As loss of the tumor suppressor p53 is a critical event in tumorigenesis, we studied the genetic mechanisms by which the remaining p53 wild-type allele was lost in Msh3 Table 1 ) showed mutation of p53. All p53 exons were sequenced, and mutations were found in exons 4, 5, 7, 8, 9 and 11 of Msh2 À / À p53 þ / À tumors. In contrast, no p53 mutations were detected in the Msh3
Consistent with the MMR-deficient phenotype, the majority of
tumors (0/8); however, LOH at the wild-type p53 allele occurred in almost all of the tumors (86%, 6/7) ( Figure 1d and Table 1) , suggesting a possible role for MSH3 in CIN. LOH of the wild-type p53 allele was also found in some Msh2
Msh3-deficient MEFs are defective in DSBR In yeast, MSH2-MSH3 is involved in the processing of SSA recombination intermediates during certain forms of homologous recombination, 5 and loss of this function might result in defective DSBR and contribute to the LOH phenotype in the tumors of
To investigate whether mouse MSH3 functions as part of the MSH2-MSH3 complex in the repair of DNA breaks, we first analyzed metaphases of untreated primary mouse embryonic fibroblast (MEF) cell lines.
Msh3
À / À and Msh2 À / À MEFs both showed a significant increase in chromatid breaks (Figures 2a and b) , further indicating a defective DSBR response. As the number of breaks in Msh6 À / À cells was not significantly different from that in wild-type cells ND  ND  wt  42  ND  ND  ND  wt  45  ND  ND  ND  wt  56  ND  ND  ND  ND  66  ND  ND  ND  wt  54  ND  ND  ND  ND  ND  36  64  ND  ND  ND  ND  ND  15  ND  ND  ND  ND  ND  ND  wt  19  ND  ND  ND  ND  ND  ND  wt Abbreviation: ND, not determined.
(P ¼ 0.21), loss of DSBR appears to be specifically due to the loss of MSH2-MSH3 complex function. Notably, all genotypes showed similar numbers of translocations.
To further analyze the observed DSBR defect, Msh3 À / À cells were subjected to a low dose of ionizing radiation (1 Gy), and efficient resolution of DSBs was subsequently evaluated by counting gH2AX foci in the cell nuclei (Figure 2c ). We did not observe a difference in the number of gH2AX foci 1 h after irradiation (Supplementary Figure S1) , which suggests that both wild-type and Msh3 À / À MEFs had a comparable accumulation of DSBs at early time points and that gH2AX signaling is intact in Msh3 À / À cells. However, 2 h after irradiation, the majority of wildtype cells (95%) showed background levels of 0-10 gH2AX foci per nucleus in contrast to only 45% of Msh3 À / À cells (Supplementary Figure S1) . Even 6 h post irradiation, only 70% of Msh3 À / À cells were able to adequately resolve DSBs (Po0.001, Figure 2d) , and an increase of more than 10 gH2AX foci per nucleus could be seen in the remaining 30% of nuclei. Taken together, these data demonstrate a moderate DSBR defect in Msh3-deficient cells that is revealed by a delay in resolving DSBs.
Msh3 deletion is associated with CIN in p53-deficient tumors To examine whether loss of MSH3 does leads to CIN during tumorigenesis, we used spectral karyotyping (SKY) to determine whether lymphomas of Msh3-deficient mice displayed any gross chromosomal abnormalities. In contrast to Msh2
tumor cells, which showed close to normal ploidy (40 chromosomes/cell, Table 2 ), Msh3 À / À p53 À / À tumor cell karyotypes showed increased CIN characterized by significantly increased aneuploidy (55 chromosomes/cell, Po0.001), translocations, deletions, duplications and breaks (Figure 3) . No specific recurring chromosomal aberrations were found, indicating that loss of MSH3 induces general CIN. However, the type of chromosomal changes between genotypes tended to be different: Msh3
À / À and Msh2 À / À p53 À / À tumor cells showed about two times more translocations compared with p53 À / À cells (1.2 and 0.9 vs 0.5 per cell, Table 2 ), suggesting that the DSBR defect associated with loss of the MSH2-MSH3 complex that was observed earlier contributes to this type of chromosomal rearrangement. In contrast, a trend toward slightly higher numbers of deletions and duplications was observed in Msh3
À / À cells, reflecting the aneuploidy phenotype that is associated with the p53 À / À tumor background. To study the increase in CIN in Msh3/p53 tumors in more detail, we used the lymphoma samples that were used for SKY analysis in array comparative genomic hybridization (aCGH) to analyze genome-wide copy-number variation (CNV). As loss of Msh3 induces sarcomagenesis, we also analyzed two groups of Msh3 À / À p53 þ / À and p53 À / À sarcomas (Supplementary Figure S2) . Again, no increase in CNV was found to recur between samples at specific genomic regions, indicating general CIN.
Compared with Msh2
À / À p53 À / À lymphoma samples, in which CNV was uncommon, this type of instability was significantly increased in Msh3 À / À p53 À / À and p53 À / À lymphomas ( Figure 4) . Figure S3 ) and subsequent cluster analysis (Supplementary Figure S4) revealed that both p53 À / À and Msh3
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Log2 ratio distributions of gains and losses (Supplementary
lymphomas showed a significant increase in CNV (cluster 1) compared with Msh2 À / À p53 À / À tumors (cluster 3). Msh3
À / À p53 À / À and p53 À / À lymphoma samples clustered together (cluster 1) that indicates the overall distribution of CNVs throughout the genome in Msh3 À / À p53 À / À tumors was similar to that of p53 À / À tumors and that loss of MSH3 does not induce a specific pattern of CNV distribution. Interestingly, the Msh3/p53 and p53 sarcoma samples (cluster 2) only showed a moderate increase in CNV compared with Msh3/p53 and p53 lymphoma samples. However, the CNV phenotype in Msh3/p53 sarcomas was significantly more severe than that found in Msh2/p53 lymphoma samples. Taken together, these results confirm that loss of MSH3, but not MSH2, is associated with an increase in overall CIN in tumor genomes and that the amount of CIN depends on the underlying predisposing genetic background and the tissue-specific context.
DISCUSSION
The MMR proteins MSH2, MSH6, MLH1 and PMS2 all have a major and well-described role in MMR, and mutations in these genes have been found in patients with HNPCC/LS. Until now, no mutations have been found in the other MMR proteins MSH3, MLH3 and EXO1 that could directly link them to the development of familial colorectal cancer. Although intestinal tumors developed in Msh3 13 and Mlh3 32 knockout mice late in life, these proteins appear to have a less pronounced role in MMR and tumor Chromosome copy-number changes were analyzed as described before. 42 To account for tumor heterogeneity, large segments with low-level copy-number changes were considered as important as small segments with high-level changes, and no arbitrary log2 ratio was used. %, percentage of samples that showed gain (red) or loss (green). L, lymphoma; S, sarcoma.
suppression. However, they have been implicated in other processes aside from MMR: apart from their roles in class switch recombination and somatic hypermutation, [33] [34] [35] [36] MLH3 is essential for processing DSBs at crossovers during meiosis, 37 and EXO1 has been identified as a key mediator of DNA end resection during DSBR.
38 Surprisingly, it has recently been found that MSH3 protein expression is higher in the majority of murine tissues when compared with MSH6, suggesting important and specific roles for MSH2-MSH3 in DNA repair and genomic instability. 24 The similar phenotype of late-onset tumors with mild MSI that appeared in Msh3 À / À and Exo1 À / À mice led us to hypothesize a role for MSH3 in tumor suppression via DSBR and maintenance of chromosomal stability. In this study, we showed that, in mice, loss of Msh3 leads to accumulation of unrepaired DSBs and to a shift in tumor spectrum with increased CIN on a p53-driven tumor predisposing background.
As described before, 25 mice with combined Msh2 and p53 ablation show independent segregation of the MSI phenotype compared with p53 À / À alone, which suggests that loss of Msh2 is dominant over the p53 À / À phenotype. Furthermore, their synergism in tumorigenesis suggests that they are not genetically epistatic. In contrast, Msh3
À / À p53 À / À mice show features that are more similar to the p53 À / À phenotype. The lack of synergism in tumorigenesis and the shift in tumor spectrum toward sarcomagenesis suggest that MSH3 might not be involved in tumor initiation but rather in tumor progression by modulating the p53-deficient phenotype. Interestingly, loss of p53 did not accelerate gastrointestinal tumorigenesis of Msh3 À / À mice, as we only detected a small number of gastrointestinal carcinomas in Msh3/p53-mutant mice (Figure 1b) . As loss of MSH3 is associated with a variety of human cancer types, its effects might be evident on other predisposing backgrounds, implicating MSH3 as a general modulator of cancer phenotypes. The contribution of Msh3 deletion to tumorigenesis, however, depends on the genetic context and subsequent mechanism of tumorigenesis in different tissues, as Msh3 À / À Apc 1638N mice did not show a different tumor onset or phenotype compared with Apc 1638N mice. 39 Because of the strong aneuploidy phenotype caused by loss of p53, 40, 41 it was not immediately clear whether loss of Msh3 contributed to the increase in CIN in Msh3 À / À p53 À / À tumors. However, although there was only a limited number of tumor samples available for SKY analysis, we observed differences between tumors with combined Msh3/p53 deficiency and single p53 deficiency with a trend toward an increase in the average number of translocations per cell for Msh3 À / À p53 À / À tumors compared with p53 À / À alone, indicating defective DSBR caused by loss of the MSH2-MSH3 complex in these tumors. This defect in DSBR was also visible when we counted chromosomal aberrations in metaphase spreads, showing a significant increase in chromatid breaks in Msh3 À / À and Msh2 À / À MEFs. Interestingly, here the number of translocations was not significantly different between wild-type, Msh3
À / À and Msh2 À / À MEFs, which might be due to technical difficulties with scoring translocations in regular metaphase spreads. Alternatively, these data suggest that loss of MSH2-MSH3-dependent DSBR results in an increase in the number of translocations during the clonal outgrowth of p53-deficient tumors and contributes to p53-driven tumorigenesis. The amount of CIN represented by CNV, however, is significantly increased in (Figure 4 and Supplementary Figure S2 ) compared with the CNV phenotype in p53 þ / À tumors from our previous study, 42 which indicates that loss of Msh3 is contributing to the CIN phenotype in Msh3 À / À p53 þ / À tumors. Our observations indicate a dual function for the MutSb complex in genome maintenance and tumor suppression ( Figure 5 ). Msh2-deficient mice display a strong MMR defect with accumulation of mutations and low CIN, indicating the essential role for MSH2 in MMR. On the other hand, a moderate DSBR defect is associated with the loss of either MSH2 or MSH3, whereas the mild phenotypes with regard to CIN and tumorigenesis that are associated with the loss of MSH2-MSH3-dependent DSBR are difficult to observe in the dominant MMR tumor phenotype of Msh2-deficient mice, we were able to study them by deleting Msh3 on the appropriate tumor predisposing background. Because the DSBR defect is not as severe as the defect caused by loss of other canonical DSBR proteins, this further suggests a role for MSH3 in the repair of a subset of DSBs, possibly substrates of the SSA pathway. 6, 7 Interestingly, loss of MSH3 was shown to be associated with accelerated tumor progression in MLH1-deficient colorectal cancers, and it was suggested that the effect of MSH3 loss on tumor progression might be related to another function of MSH3 unrelated to MMR, implicating its role in DNA DSBR by SSA. 3 It remains unclear whether the role of MSH3 in DSBR is dependent on its recruitment via the MMR pathway, either during the process of homeologous recombination or when small insertions/ deletions or DNA mismatches 43 on opposite strands are in close proximity so as to mediate the formation of DSBs during the MMR process, or whether MSH2-MSH3 could instead be recruited directly to sites of DSBs. Regardless, MSH3 was shown to colocalize with gH2AX and DSB foci following genotoxic stress, 44, 45 which suggests that it might be directly involved in a subset of DSBR events.
Despite the moderate defect in DSBR, Msh3-deficient mice showed a significant increase in sarcomagenesis, suggesting that loss of MSH3 targets sarcoma tumor suppressor genes and modulates p53-dependent tumorigenesis. When we analyzed lymphomas and sarcomas for genomic instability, Msh3
À / À and p53 À / À lymphomas showed the largest increase in CNV, whereas Msh2 À / À p53 À / À mice displayed a low CNV phenotype. Interestingly, both Msh3/p53 and p53 sarcomas displayed significantly more CNV than Msh2/p53 lymphomas, but less CNV than Msh3/p53 and p53 lymphomas, and clustered together based on their moderate CNV profile. This indicates that loss of Msh3 causes a repair defect that contributes to genomic instability in a tissue-specific manner and promotes p53-driven sarcomagenesis. As the sarcomas in our mouse cohorts are microsatellite stable, the increase in sarcoma incidence in Msh3/ p53 mutant mice is likely caused by loss of Msh3-dependent DSBR that contributes to the moderate CIN that is associated with sarcomagenesis. However, loss of Msh3-dependent MMR Figure 5 . Model representing different functions of the Mutsb (MSH2-MSH3) complex. Deletion of Msh2 induces a strong MMR defect and a moderate DSBR defect, leading to a dominant tumor phenotype with early-onset tumors that are MSI-high and chromosomally stable. Deletion of Msh3 revealed a moderate DSBR defect next to the previously described moderate MMR defect, resulting in a modulated tumor phenotype of late-onset tumors that were MSIlow and showed increased CIN.
might also have a role in p53-dependent sarcomagenesis by resulting in a low-level mutator phenotype involving base substitutions that might be difficult to detect. 2, 43 In conclusion, our data indicate for the first time that the MSH2-MSH3 protein complex is involved in tumorigenesis through maintenance of chromosomal stability. In contrast to the MutSa complex (MSH2-MSH6), which has a dominant role in genome maintenance by MMR, MSH2-MSH3 functions both in MMR, indicated by an MSI-L phenotype, and DSBR, as has been recently shown in yeast. 7 Loss of MSH3 can therefore contribute to tumorigenesis in two ways: by a mild MMR defect leading to MSI-L and low-level mutation accumulation and by a DSBR defect that leads to a moderate increase in CIN. As most sporadic colorectal cancers are CIN (85%), 46 the MSH2-MSH3 complex might have an important role in suppression of late-onset sporadic cancers that are MSI-L. Future studies should therefore include the analysis of Msh3 loss on multiple tumorigenic backgrounds to assess a more specific role for MSH3 in tumorigenesis.
MATERIALS AND METHODS
Animals, tumors and survival
Msh2
À / À , Msh3 À / À and Msh6 À / À knockout mice were previously generated in our lab. 13, 28, 47 p53 À / À knockout mice 48 were purchased from Jackson Laboratories (Bar Harbor, ME, USA). All mice were on a congenic C57BL/6 background. Mice were intercrossed as described and observed until they became morbid or moribund. Tumors were removed and fixed in 10% buffered formalin or frozen at À 150 1C. After paraffin embedding of fixed tissue, sections were stained with hematoxylin and eosin. Statistical analysis of tumor incidence was completed using IBM SPSS Statistics version 20.0 (IBM Corp., Armonk, NY, USA). The KaplanMeier method was used to compare curves for survival, with significance evaluated by two-sided log rank statistics. A w 2 -test was used to assess the influence of genotype on the tumor spectrum.
Microsatellite instability, LOH and mutational analysis of p53
For MSI analysis, the D7Mit91 and D17Mit123 microsatellite loci were amplified from normal and tumor DNA and analyzed as previously described. 39 Tumor DNA was also serially diluted and analyzed for loss of the wild-type p53 allele as previously described. 42 To analyze tumors for p53 mutations, primers amplifying all exons of p53 (including both transcript variants of exon 11) were used as described, 49 followed by DNA sequencing.
Chromatid break and double-strand break analysis Primary MEFs (p4-6) were treated overnight with 0.1 mg/ml colcemid (Invitrogen, Carlsbad, CA, USA) and subsequently swelled, fixed and dropped onto glass slides to prepare metaphase spreads. DNA was stained using mounting medium with DAPI (Vector Laboratories, Inc., Burlingame, CA, USA), and at least 100 metaphases in 2-3 different cell lines were analyzed per genotype.
For DSB analysis, MEFs were cultured on poly-L-lysine-coated slides (Sigma, St Louis, MO, USA), irradiated with 1 Gy and incubated at 37 1C for 30 min to 6 h. Cells were fixed with cold 1:1 methanol:acetone for 5 min, and washed twice with cold PBS for 5 min. After blocking with 10% FBS in PBS, cells were incubated overnight with a mouse monoclonal gH2AX antibody (Upstate, Billerica, MA, USA; 1:500). Cells were again washed twice in cold PBS for 5 min and incubated for 1 h at room temperature with an Alexa Fluor 488-labeled goat anti-mouse antibody (Invitrogen). DNA was stained using mounting medium with DAPI. The experiment was repeated three times for two different cell lines per genotype, and a minimum of 100 cells were analyzed each time.
Metaphases and foci were counted using an Olympus BX61 microscope (Olympus America Inc., Center Valley, PA, USA) with Sensicam QE cooled CCD camera (PCO, Kelheim, Germany). Significant differences between cell lines in the number of breaks or gH2AX foci were calculated using an independent two-sample t-test of equal variance.
Spectral karyotyping
Thymic lymphomas were dissociated, filtered and resuspended as described. 50 To prepare metaphase spreads, cells were treated with colcemid for 3-6 h, swelled, fixed and dropped onto clean glass slides inside a humidity chamber. SKY was performed as previously described. 51 Slides were hybridized with the combinatorially labeled whole chromosome painting probes (Applied Spectral Imaging, Inc., Carlsbad, CA, USA), and metaphase images were captured using the Applied Spectral Imaging interferometer on an epifluorescence microscope (Carl Zeiss Microscopy, Thornwood, NY, USA). SKY karyotypes were then analyzed with SkyView version 1.62 (Applied Spectral Imaging, Inc.). Metaphases were captured and analyzed using the nomenclature approved by the International Committee on Standardized Genetic Nomenclature for Mice (http://www.informatics.jax.org).
Array comparative genomic hybridization Genomic DNA was isolated from frozen tumor tissue and matched normal tail tissue using the Qiagen DNeasy kit and hybridized to NimbleGen Mouse CGH 3 Â 720K Whole-Genome Tiling Arrays (Roche NimbleGen, Inc., Madison, WI, USA) in four different experiments. To represent the wide variation of mouse sarcoma samples but also to homogenize between genotypes, groups were composed of one fibrohistiocytic, one hemangioand one spindle cell sarcoma each.
Plotting summaries of copy-number changes among all samples for each genotype was done as described before. 42 In order to compare copynumber changes between different sets of samples, distributions of the (log2) ratios for the segmented data were plotted for each sample. The tails of this distribution (weight) were used to indicate the amount of CIN; that is, for each distribution, the proportion of data points 43 s.d. of the distribution with the lowest variance was computed on the left and right tails, that is, relative copy-number increase (gain) or decrease (loss) according to the aCGH data. Samples were subsequently clustered using the k-means clustering algorithm. Consistency of the clusters obtained was evaluated using the silhouette method.
